Tilray has announced a number of strategic initiatives to mark the next phase of its global growth, expanding across healthcare, cannabis and beverages, strengthening its ability to expand internationally and capture emerging market opportunities.

Irwin D. Simon, President and CEO of Tilray Brands, stated: “Tilray Brands is setting the pace for global innovation in healthcare, cannabis and craft beverages – each a distinct growth engine on our platform. This is a crucial time as we enter the next phase of global growth. We are executing carefully against our strategic plan by expanding our international brand growth icon position and Brewver’s international medical icon position. At the same time, our brands, We maintain the financial flexibility to invest behind infrastructure and capabilities.Together, these actions position Tilray as a broad and diversified global platform with multiple near- and long-term growth drivers, and one of the most dynamic and exciting consumer companies today.

© Tilray Marks

Tilray expands UK Medical Platform with acquisition of Lyphe
Tilray acquired Lyphe Group, a leading UK-based medical cannabis clinic and digital pharmacy platform, with Lyphe Dispensary dispensing around 150,000 units and Lyphe Clinic treating over 16,000 patients to date, anchoring and expanding Tilray Medical’s footprint in one of Europe’s largest and most dynamic healthcare markets. The addition of Lyphe strengthens Tilray’s vertically integrated medical ecosystem, combining clinical services, patient access and pharmaceutical distribution. Through Lyphe’s online clinic and pharmacy platform, Tilray will improve access to medical cannabis while accelerating its traditional prescription drug delivery capabilities, creating a seamless digital patient experience.

Most importantly, with the addition of the Lyphe Group, Tilray Medical is establishing its first fully vertically integrated medical platform, which combines the cultivation and production of pharmaceutical-grade medical cannabis with clinical care, distribution services and pharmaceutical distribution. The integration of Lyphe’s highly skilled patient care team further differentiates this model, enabling a more personalized, unified and comprehensive approach to patient care and outcomes. Tilray will also leverage CC Pharma’s established scale, supply capabilities and purchasing power to supply medicines more efficiently through the Lyphe platform, supporting the wider needs of UK patients and further strengthening Tilray’s European pharmaceutical distribution network.

Rajnish Ohri, International President, Tilray Brands, said: “I am proud to welcome the Lyphe team to Tilray, bringing deep clinical experience and a strong patient-first approach, which immediately strengthens our capabilities. This acquisition marks an important step in Tilray Medical’s continued expansion as a global healthcare platform. We look forward to enhancing our capabilities, our ability to serve UK patients, and the international medical ecosystem in 2027. to build a fully connected, consistent, high-quality care while expanding access to cannabis and traditional therapies.

BrewDog and the beverage platform: Accelerate growth, scale globally and invest in expansion
Six weeks after Tilray acquired BrewDog, the company has moved with speed and discipline to stabilize and strengthen the platform, positioning the brand for its next phase of growth. Tilray has stabilized beer volumes, maintained service levels across channels to ensure consistent stock availability and has begun onboarding new distribution and strategic partners to support expansion.

Mr Simon added: “Our priorities are clear: to strengthen BrewDog, accelerate innovation and scale our global beverage platform. We are already taking decisive steps to reinvest in the BrewDog brand, the innovation pipeline and the brewpub experience, and we see a clear path to rebuilding BrewDog. In the US, we are leveraging our infrastructure and distribution network for our broader beverage portfolio in key growth markets, including the Middle East and India. to scale and support the growth of our American craft brands and global partners like Carlsberg across the US.

Tilray expects the BrewDog business to be cash flow positive by 2027 and is investing in the brand and to revitalize and modernize the existing brewpub estate – areas that have seen limited investment in recent years. This provides a strong foundation for improving performance through targeted operational improvements and focused brand building. These efforts are focused on reimagining the brewpub experience to better connect with today’s consumers to ensure long-term brand relevance. As part of enhancing the venue experience with modern activations, strengthening brand engagement and aligning with evolving consumer preferences, Tilray will invest in a “brewpub of the future” at one of its existing locations, allowing it to analyze, evaluate and recommend future changes to its brewpub network. Tilray BrewDog is building a more compelling platform for the future.

Tilray is seeing strong and growing demand for its American craft portfolio in the UK, creating near-term opportunities to expand distribution and build brand presence in the market. Building on this momentum, the Company plans to launch Hi*Ball Energy in the UK in May, further expanding the beverage offering and increasing consumer demand in the growing functional drink category.

Positioned for US reprogramming and medical cannabis options
In the United States, we are closely following medical cannabis rescheduling and actively engaging with legislators and regulators as they evaluate and work on this important drug policy development. We are also evaluating our participation in the Center for Medicare and Medicaid Innovation pilot program, an opportunity to partner with Healthcare Organizations and oncology practices to provide hemp-derived medical cannabis to underserved and vulnerable patients, provide safe and therapeutic access to medical cannabinoids, and collect data on patient outcomes.

Denise Faltisch, Director of Strategy and Head of M&A, Tilray Brands, stated: “In retrospect, Tilray Medical is strategically positioned to participate in the US medical cannabis market, given our proven track record of operating at scale in highly regulated medical cannabis markets globally, our pharmaceutical quality systems and scientific research, backed by scientific education and scientific research. It will happen in the near term and when it does, we are well positioned to seize the opportunity.”

Through our global Tilray Medical platform, Tilray Medical offers extensive experience in pharmaceutical-grade cultivation, manufacturing and distribution, clinical research and regulatory expertise based in more than 20 markets worldwide. Tilray Medical has helped hundreds of thousands of patients worldwide and offers an extensive portfolio of medical cannabis products, including CBD and THC: beverages, edibles and topicals.

Tilray Introduces ATM Program to Accelerate Global Beverage Expansion
To support this next phase of growth, Tilray has also announced that it will introduce a market equity program (the “ATM program”) of up to $180 million to improve financial flexibility and invest behind its global beverage platform. The ATM program will be managed by Jefferies LLC, TD Securities (USA) LLC and Roth Capital Partners LLC.